Genelux posted a net loss of $9.47 million in the quarter ended June 30, 2026, widening from $7.46 million a year earlier.
Research and development expense rose 36.78% to $6.51 million, driven by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 trial.
General and administrative costs edged up 3.39% to $3.14 million, on higher stock-based compensation partly offset by lower professional services.
Revenue was unchanged, with no revenue recognized in the first half; net loss widened to $18.4 million from $14.95 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $18.7 million at June 30, 2026, expected to last into first-quarter 2027.
GNLX•
